Decoy Therapeutics Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.94
- 52-Week Range
- $0.84 – $16.92
- Market Cap
- $2.10M
- P/E (TTM)
- 0.07
- EPS (TTM)
- 12.74
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.08
- PEG Ratio
- —
- Return on Equity
- -827.77%
- Return on Assets
- -73.35%
- Gross Margin
- 0.00%
- Operating Margin
- -2679.30%
- Profit Margin
- 0.00%
- Current Ratio
- 1.83
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- $-509.88K
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-7.60M
Market Snapshot
About
Decoy Therapeutics Inc. is a biotechnology company focused on developing novel therapies for immune-mediated diseases. The company's approach involves using decoy receptor technology to intercept and neutralize disease-causing proteins. Decoy Therapeutics is advancing a pipeline of drug candidates through preclinical and clinical development stages. The company operates in the competitive biopharmaceutical sector with focus on innovative treatment mechanisms.